Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Agenus Inc. - Common Stock (NQ:AGEN)

6.070 +0.560 (+10.16%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agenus Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
7 Analyst-Backed Stocks With Promising 10-Bagger Potential
Although true 10-baggers are by nature extremely difficult to come by, these analyst-backed stocks may offer a decent shot. 
Via InvestorPlace
Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Agenus Inc.
Via Business Wire
3 Biotech Stocks with Potential for Major Medical Breakthroughs in 2024
There are several potential biotech breakthroughs likely to occur in 2024, and these three biotech stocks could see substantial gains 
Via InvestorPlace
Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population
From Agenus Inc.
Via Business Wire
Agenus's Earnings Outlook
Via Benzinga
Why LQR House Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Shares of LQR House Inc. (NASDAQ: LQR) rose sharply in pre-market trading. Borg's investor group has acquired a 20% stake in LQR House. LQR House shares jumped 16.1% to $4.25 in pre-market trading Here... 
Via Benzinga
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Agenus Inc.
Via Business Wire
Agenus to Participate in B. Riley Healthcare Conference
From Agenus Inc.
Via Business Wire
2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street
These two biotech stocks could be poised for a trend reversal. 
Via The Motley Fool
Botensilimab/Balstilimab Data in Neoadjuvant Colorectal Cancer Selected for ASCO-GI 2024
From Agenus Inc.
Via Business Wire
Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program
From Agenus Inc.
Via Business Wire
Agenus Reports Third Quarter 2023 Results
From Agenus Inc.
Via Business Wire
Agenus to Provide Third Quarter 2023 Financial Report and Corporate Update
From Agenus Inc.
Via Business Wire
Textainer Group, Roivant Sciences And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded lower this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Agenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma
From Agenus Inc.
Via Business Wire
ESMO 2023: Agenus’ Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma Subtypes
From Agenus Inc.
Via Business Wire
Agenus Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer
From Agenus Inc.
Via Business Wire
Agenus To Host BOT/BAL Program Update at ESMO 2023
From Agenus Inc.
Via Business Wire
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Agenus Inc.
Via Business Wire
HEICO, Canaan And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded higher this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session. HEICO Corporation (NYSE: HEI) shares tumbled 5.3% to $159.01... 
Via Benzinga
3 Magnificent Growth Stocks to Buy on the Dip
These three biotech stocks are attractive buys right now. 
Via The Motley Fool
Agenus to Participate in September Investor Conferences
From Agenus Inc.
Via Business Wire
Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers
From Agenus Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
SaponiQx Announces Breakthrough in Scaling Up of STIMULON™ Cultured Plant Cell Adjuvant
From SaponiQx
Via Business Wire
Agenus Reports Second Quarter 2023 Results
From Agenus Inc.
Via Business Wire
Agenus Botensilimab/Balstilimab Data Update in Sarcomas Selected for Oral Presentation at ESMO 2023
From Agenus Inc.
Via Business Wire
Agenus to Provide Second Quarter 2023 Financial Report and Corporate Update
From Agenus
Via Business Wire
Agenus Expands Executive Leadership Team
From Agenus Inc.
Via Business Wire
ESMO GI Data: Agenus' Botensilimab/Balstilimab Combination Achieves Unprecedented Survival in Advanced Colorectal Cancer
From Agenus
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.